source
- Celldex halts skin disease program after barzolvolimab fails phase 2 trialCelldex Therapeutics announced it is discontinuing development of its anti‑KIT antibody barzolvolimab for chronic skin disorders after the drug failed to meet its primary endpoint in a phase 2 stud…
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…